Zetran (injection)
Generic name:diazepam (injection) [ dye-AZ-e-pam ]
Brand names: Valium, Zetran
Drug classes:Benzodiazepine anticonvulsants, Benzodiazepines
The Zetran brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.
What is Zetran?
Zetran is a benzodiazepine (ben-zoe-dye-AZE-eh-peen) that is used to treat anxiety disorders, alcohol withdrawal symptoms, or muscle spasms. This medicine injection is also used to treat a seizure emergency called status epilepticus.
Zetran is sometimes used as a sedative to help you relax before having surgery or other medical procedure.
Zetran may also be used for purposes not listed in this medication guide.
Warnings
Tell your doctor about all your current medicines and any you start or stop using. Zetran can slow or stop your breathing, especially if you have recently used an opioid medication or alcohol.
If you receive Zetran during an emergency, make sure any follow-up doctor knows you received Zetran.
Before taking this medicine
You should not be treated with Zetran if you are allergic to it. You may not be able to receive a this medicine if you have glaucoma.
If possible during an emergency, tell your medical caregivers if you've ever had:
glaucoma;
asthma, emphysema, bronchitis, chronic obstructive pulmonary disorder (COPD), or other breathing problems;
kidney or liver disease;
mental illness, depression, or suicidal thoughts or behavior;
heart disease; or
if you have recently used alcohol, sedatives, tranquilizers, or opioid medications.
Zetran may harm an unborn baby, and generally should not be used during pregnancy. However, status epilepticus is a life-threatening condition and the benefit of receiving this medicine to treat it may outweigh any risk to the unborn baby. Tell your doctor if you are pregnant.
Ask a doctor if it is safe to breastfeed while using this medicine.
If possible during an emergency, tell your medical caregivers if you are pregnant or breas...
